The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 352.00
Bid: 350.00
Ask: 352.00
Change: 14.00 (4.14%)
Spread: 2.00 (0.571%)
Open: 348.00
High: 353.00
Low: 342.00
Prev. Close: 338.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

Thu, 28th Mar 2024 08:08

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

It is also despite unrevised numbers from the Office for National Statistics confirming the UK entered a technical recession in the fourth quarter of 2024.

"The only thing that investors need is the Federal Reserve rate cut dream to stay alive for the June meeting. And for now, that's the case. Activity on Fed funds futures gives around 64% chance for a June rate cut," said Swissquote Bank analyst Ipek Ozkardeskaya.

"But note that, this probability was around 75% last week and it's coming lower as many investors think that the Fed won't be able to cut the rates with robust growth and bumpy inflation. And indeed, the US latest GDP update is due today and is expected to confirm an above 3% growth for the US economy in the last quarter of last year, down from almost 5% printed a quarter earlier. These levels don’t call for an imminent Fed cut."

In early corporate news, JD Sports said it outperformed the sportswear market in its full-year, with like-for-like sales growing.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.3% at 7,955.13

----------

Hang Seng: up 1.1% at 16,564.84

Nikkei 225: closed down 1.5% at 40,168.07

S&P/ASX 200: closed up 1.0% at 7,896.90

----------

DJIA: closed up 477.75 points, 1.2%, at 39,760.08

S&P 500: closed up 44.91 points, 0.9%, at 5,248.49

Nasdaq Composite: closed up 83.82 points, 0.5%, to 16,399.52

----------

EUR: down at USD1.0802 (USD1.0823)

GBP: down at USD1.2615 (USD1.2630)

USD: up at JPY151.38 (JPY151.35)

Gold: up at USD2,193.16 per ounce (USD2,190.33)

(Brent): up at USD85.66 a barrel (USD85.41)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

08:55 GMT Germany unemployment

09:00 GMT eurozone money supply

12:30 GMT US GDP

12:30 GMT US initial jobless claims

14:00 GMT US pending home sales

14:00 GMT US Michigan consumer sentiment index

15:00 GMT US Kansas City Fed manufacturing activity

----------

The UK slipped into a technical recession in the fourth quarter of 2023, numbers from the Office for National Statistics confirmed on Thursday. UK gross domestic product slumped 0.3% in the three months to December from a quarter earlier, unchanged from initial ONS numbers provided in February. The UK economy had declined 0.1% quarter-on-quarter in the third-quarter of 2023. It means the UK has entered a technical recession at the end of last year, which is generally defined as two successive quarterly falls in gross domestic product. In output terms for the fourth quarter, the ONS said there were falls in all three main sectors: services down 0.1%, production down 1.1% and construction output down 0.9%. Meanwhile, in expenditure terms, there was a fall in the volume of net trade, household consumption and gross capital formation, according to the ONS, partially offset by an increase in government consumption.

----------

The US Federal Reserve should either scale back or delay its interest rate cuts in response to "disappointing" inflation data, a senior Federal Reserve official said. "In my view, it is appropriate to reduce the overall number of rate cuts or push them further into the future in response to the recent data," Fed Governor Christopher Waller told a conference in New York. "Shorter-term inflation measures are now telling me that progress [in reducing inflation] has slowed and may have stalled. But we will need more data to know that," he added. "I see economic output and the labour market showing continued strength, while progress in reducing inflation has slowed," Waller said. "Because of these signs, I see no rush in taking the step of beginning to ease monetary policy," he continued.

----------

BROKER RATING CHANGES

----------

Jefferies cuts Diploma to 'hold' (buy) - price target 3,950 (3,750) pence

----------

Exane BNP cuts Aviva to 'underperform' ('neutral') - target 420 (445) pence

----------

Exane BNP cuts Legal & General to 'neutral' ('outperform') - target 270 (280) pence

----------

COMPANIES - FTSE 100

----------

Retailer JD Sports said it outperformed the sportswear market in the 53 weeks that ended February 3. It said like-for-like sales rose 4.2% on-year and up 8.4% organically on a constant currency basis, while total sales grew 3.6% to around GBP10.5 billion. It expects pretax profit to be in line with its guided range of GBP915 million to GBP935 million, down from GBP991.4 million a year earlier. "We made good strategic progress, opening 215 new JD stores, and focusing our effort on developing JD and enhancing EPS through taking full control of ISRG and MIG," said Chief Executive Officer Regis Schultz. It outlined its initial financial 2025 profit forecast of GBP900 million to GBP980 million, while saying trading in the new financial year-to-date is in line with its expectations after seven weeks. Schultz continued: "Looking ahead, the current trading environment remains challenging due to less product innovation and elevated promotional activity, especially online. We anticipate trading conditions will improve as we move through the year, helped by a busy sporting summer and softer comparatives with last year."

----------

The UK Competition & Markets Authority decided not to refer the planned acquisition by FTSE 100-listed insurer Aviva of AIG's life-insurance and retirement-services division AIG Life to a phase 2 investigation. The UK competition watchdog said this decision was based on the information currently available and that a further announcement on the decision will be made "as soon as is reasonably practicable". In February, the CMA said it was investigating the deal, saying it could reduce competition in the UK services sector.

----------

COMPANIES - FTSE 250

----------

Automated test and assurance solutions provider Spirent said it agreed to a GBP1.16 billion takeover from Keysight Technologies. Spirent said the offer was superior to Viavi's existing GBP1.01 billion bid. The latest offer rates Spirent at 201.5 pence per share, 199.0p in cash and 2.5p in a special dividend. Spirent Chair Bill Thomas commented: "The board of Spirent is pleased to recommend Keysight's cash offer for Spirent, which is an increase of 15% to the Viavi proposal." Chief Executive Officer Eric Updyke added: "Keysight's offer for Spirent will provide further opportunities for our employees and strengthens our customer offering, given Keysight's technology expertise, capabilities and robust global platform with its breadth and depth of industry-leading solutions."

----------

OTHER COMPANIES

----------

Cancer and immunological diseases treatments developer Hutchmed said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. If accepted, the new label indication for savolitinib will be expanded to include treatment-naive patients, those that have not received any treatment, in China. Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. "More than a third of the world's lung cancer patients are in China," Hutchmed noted.

----------

Troubled utility Thames Water has said its shareholders will not be injecting the first GBP500 million of funding that was agreed last summer into the group as industry regulations make its business plan "uninvestible". Thames Water – the UK's biggest water supplier with 15 million households across London and the South East – said the funding plan drawn up last July was subject to conditions, including a business plan that is supported by "appropriate regulatory arrangements". It said the regulations being imposed by industry watchdog Ofwat "make the PR24 plan "uninvestible", and as a result the shareholder support letter from last July "has not been satisfied".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
11 Mar 2022 10:38

IN BRIEF: Hutchmed China shares fall as US listing under threat

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Says its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

Read more
7 Mar 2022 10:04

Hutchmed receives USD15 million from AstraZeneca for Saffron progress

(Alliance News) - Hutchmed (China) Ltd on Monday said it has received USD15 million from AstraZeneca PLC as start-up activities for Saffron commenced.

Read more
3 Mar 2022 13:02

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Mar 2022 12:54

Hutchmed China losses widen as it appoints new CEO

(Sharecast News) - Hutchmed China reported a 56% increase in total revenues in its full-year results on Thursday, to $356.1m (£266.17m), although its losses widened, as it announced the departure of its chief executive officer and the appointment of his replacement.

Read more
1 Mar 2022 20:32

TRADING UPDATES: Hutchmed in Macau boost; UP Global success in Germany

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
24 Feb 2022 15:54

UK earnings, trading statements calendar - next 7 days

Friday 25 February 
Evraz PLCFull Year Results
IMI PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Jupiter Fund Management PLCFull Year Results
Pearson PLCFull Year Results
Rightmove PLCFull Year Results
Monday 28 February 
Associated British Foods PLCTrading Statement
BATM Advanced Communications LtdFull Year Results
Bunzl PLCFull Year Results
CentralNic Group PLCFull Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Kitwave Group PLCFull Year Results
Kosmos Energy LtdQ4 Results
Made Tech Group PLCHalf Year Results
RHI Magnesita NVFull Year Results
Tuesday 1 March 
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Flutter Entertainment PLCFull Year Results
Hotel Chocolat Group PLCHalf Year Results
Intertek Group PLCFull Year Results
Man Group PLCFull Year Results
PCI-PAL PLCHalf Year Results
Quartix Technologies PLCFull Year Results
Reach PLCFull Year Results
Revolution Bars Group PLCHalf Year Results
Rotork PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Vitec Group PLCFull Year Results
XP Power LtdFull Year Results
Wednesday 2 March 
Polymetal International PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Vistry Group PLCFull Year Results
Nichols PLCFull Year Results
Hotel Chocolat Group PLCHalf Year Results
Devro PLCFull Year Results
KRM22 PLCFull Year Results
Supermarket Income REIT PLCHalf Year Results
Foxtons Group PLCFull Year Results
Persimmon PLCFull Year Results
Hiscox PLCFull Year Results
musicMagpie PLCFull Year Results
Vivo Energy PLCFull Year Results
Aviva PLCFull Year Results
Thursday 3 March 
Admiral Group PLCFull Year Results
Avation PLCHalf Year Results
Coats Group PLCFull Year Results
CRH PLCFull Year Results
Darktrace PLCHalf Year Results
Dotdigital GroupFull Year Results
Elementis PLCFull Year Results
Empiric Student Property PLCFull Year Results
Entain PLCFull Year Results
Franchise Brands PLCFull Year Results
Galliford Try Holdings PLCHalf Year Results
Hansard Global PLCHalf Year Results
Hutchmed (China) LtdFull Year Results
ITV PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Meggitt PLCFull Year Results
Melrose Industries PLCFull Year Results
Mondi PLCFull Year Results
PageGroup PLCFull Year Results
Rentokil Initial PLCFull Year Results
Schroders PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Synthomer PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Tritax Big Box REIT PLCFull Year Results
Tyman PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
4 Feb 2022 10:36

Hutchmed starts new phase of probe on HMPL-453 as combination therapy

Hutchmed starts new phase of probe on HMPL-453 as combination therapy

Read more
20 Jan 2022 11:03

Hutchmed begins phase one study for potential tumour treatment

Hutchmed begins phase one study for potential tumour treatment

Read more
13 Jan 2022 09:10

TOP NEWS: Retailer ASOS now to be seen on London Main Market

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Read more
12 Jan 2022 11:37

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Read more
10 Jan 2022 09:23

Hutchmed begins phase one study for potential cancer treatment

Hutchmed begins phase one study for potential cancer treatment

Read more
6 Dec 2021 10:44

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

Read more
3 Dec 2021 13:23

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

Read more
3 Dec 2021 09:54

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

Read more
24 Nov 2021 11:35

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.